Vaccines News and Research RSS Feed - Vaccines News and Research

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
Research findings could help guide development of potential treatments for HCV

Research findings could help guide development of potential treatments for HCV

Warring armies use a variety of tactics as they struggle to gain the upper hand. Among their tricks is to attack with a decoy force that occupies the defenders while an unseen force launches a separate attack that the defenders fail to notice. [More]
Scientists identify molecular 'lock' that enables Ebola virus to gain entry to cells

Scientists identify molecular 'lock' that enables Ebola virus to gain entry to cells

An international team including scientists from Albert Einstein College of Medicine of Yeshiva University and the U.S. Army Medical Research Institute of Infectious Diseases has identified the molecular "lock" that the deadly Ebola virus must pick to gain entry to cells. [More]
Liverpool scientists complete genomics studies on multidrug resistant Typhoid fever in Africa

Liverpool scientists complete genomics studies on multidrug resistant Typhoid fever in Africa

The team has completed two genomics studies on the tropical disease, a condition that is estimated to cause up to 30 million illnesses and over a quarter of a million deaths globally each year. [More]
Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer. [More]
Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people. [More]
Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system's B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines. [More]
TGen and Baylor partnership set to increase treatment options for cancer patients

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers. [More]
Existing anti-stroke drug can be effective in treating middle-ear infections

Existing anti-stroke drug can be effective in treating middle-ear infections

An existing anti-stroke drug is an effective treatment for middle-ear infections, showing the ability to suppress mucus overproduction, improve bacterial clearance and reduce hearing loss, according to researchers at Georgia State University and the University of Rochester. [More]

Canada lagging behind similar OECD countries with regard to public drug plan reimbursement

Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in public drug plans, according to a new IMS Brogan report commissioned by Rx&D. Overall, the report ranks Canada 16 out of 18 similar OECD countries. [More]
Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. [More]
SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo. [More]
Monash University researcher helps identify right type of Ebola vaccine trial

Monash University researcher helps identify right type of Ebola vaccine trial

An Australian researcher has helped identify the kind of human trial that is most effective for testing Ebola vaccines. [More]
MSR, PATH announce launch of new water treatment product

MSR, PATH announce launch of new water treatment product

Local outdoor gear manufacturer MSR (Mountain Safety Research) and Seattle-based international nonprofit organization and global health innovation leader PATH today announced the launch of a new water treatment product, the result of a five-year partnership to bring low-cost community water solutions to the global market. [More]
Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport, Inc. today announced financial results for the three and twelve-month periods ended March 31, 2015. [More]
Pre-pregnancy maternal weight has significant impact on baby's immune system

Pre-pregnancy maternal weight has significant impact on baby's immune system

Almost 60 percent of women of childbearing age in the United States are overweight or obese. Obesity is a major public health issue, and has been linked to health problems like heart disease, cancer and hypertension. It can complicate pregnancy by increasing the mother's risk of having gestational diabetes, preeclampsia, preterm birth or a baby with birth defects. Maternal obesity is also linked to several adverse health outcomes for the infant that can persist into adulthood, such as type-2 diabetes, heart disease and mortality. [More]
CMO Council announces the launch of global innovation ecosystem to advance UNICEF’s work

CMO Council announces the launch of global innovation ecosystem to advance UNICEF’s work

The Chief Marketing Officer (CMO) Council today announced the launch of a global CauseTech.net community and portal site, which is part of a new private sector initiative to crowdsource breakthrough ideas, inventions, products, and emerging technologies that can advance the work done by the UNICEF Global Innovation Center worldwide. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. [More]
Advertisement
Advertisement